No Data
No Data
No Data
No Data
No Data
Bioasis Provides Corporate Update and Announces Suspension of Operations
NEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
GlobeNewswireJun 20, 2023 17:25 ET
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Increase in Short Interest
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 19,80
Defense WorldApr 30, 2023 03:52 ET
Short Interest in Bioasis Technologies Inc. (OTCMKTS:BIOAF) Increases By 28.7%
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 32,300 shares, a growth o
Defense WorldFeb 14, 2023 04:01 ET
Bioasis Announces AGM Results and Provides Update on Financial Position
NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
GlobeNewswireFeb 3, 2023 17:41 ET
On Jan 23, 2023, Midatech Pharma PLC Received Termination Notice From Bioasis Technologies Inc. To Terminate Arrangement; On January 26 Co Terminated Securities Purchase Agreement By And Between Company And A Certain Institutional Investor
On Jan 23, 2023, Midatech Pharma PLC Received Termination Notice From Bioasis Technologies Inc. To Terminate Arrangement; On January 26 Co Terminated Securities Purchase Agreement By And Between Compa
Benzinga Real-time NewsJan 26, 2023 08:25 ET
Bioasis Technologies Inc. Announces Termination Of Arrangement Agreement With Midatech Pharma Plc
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company d
GlobeNewswireJan 23, 2023 09:25 ET
No Data
No Data